MA53098A - Médicament pour prévenir ou traiter une maladie ophtalmique associée à une néovascularisation intraoculaire et/ou à une perméabilité vasculaire intraoculaire accrues - Google Patents
Médicament pour prévenir ou traiter une maladie ophtalmique associée à une néovascularisation intraoculaire et/ou à une perméabilité vasculaire intraoculaire accruesInfo
- Publication number
- MA53098A MA53098A MA053098A MA53098A MA53098A MA 53098 A MA53098 A MA 53098A MA 053098 A MA053098 A MA 053098A MA 53098 A MA53098 A MA 53098A MA 53098 A MA53098 A MA 53098A
- Authority
- MA
- Morocco
- Prior art keywords
- medicine
- preventing
- disease associated
- vascular permeability
- ophthalmic disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016911 | 2018-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53098A true MA53098A (fr) | 2021-05-12 |
Family
ID=67479734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053098A MA53098A (fr) | 2018-02-02 | 2019-02-01 | Médicament pour prévenir ou traiter une maladie ophtalmique associée à une néovascularisation intraoculaire et/ou à une perméabilité vasculaire intraoculaire accrues |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210113529A1 (fr) |
| EP (1) | EP3747471A4 (fr) |
| JP (1) | JPWO2019151470A1 (fr) |
| KR (1) | KR20200116953A (fr) |
| CN (1) | CN111683682A (fr) |
| AU (1) | AU2019214265A1 (fr) |
| BR (1) | BR112020015567A2 (fr) |
| CA (1) | CA3089952A1 (fr) |
| IL (1) | IL275603A (fr) |
| JO (1) | JOP20200186A1 (fr) |
| MA (1) | MA53098A (fr) |
| MX (1) | MX2020007948A (fr) |
| PH (1) | PH12020551015A1 (fr) |
| RU (1) | RU2020128700A (fr) |
| SG (1) | SG11202006255UA (fr) |
| WO (1) | WO2019151470A1 (fr) |
| ZA (1) | ZA202004327B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021148439A1 (fr) * | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de stimulation de la fonction cérébrovasculaire |
| WO2021163355A1 (fr) * | 2020-02-11 | 2021-08-19 | Arena Pharmaceuticals, Inc. | Formulations et méthodes de traitement d'affections liées au récepteur s1p1 |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100431534C (zh) | 2003-06-24 | 2008-11-12 | 康涅狄格大学 | 血管内皮鞘氨醇-1-磷酸受体拮抗剂在制备药物中的应用 |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| EP1798226A4 (fr) | 2004-08-04 | 2009-06-17 | Taisho Pharmaceutical Co Ltd | Derive de traizol |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| WO2007089018A1 (fr) | 2006-02-03 | 2007-08-09 | Taisho Pharmaceutical Co., Ltd. | Dérivé de triazole |
| CN101415687B (zh) | 2006-02-06 | 2012-02-08 | 大正制药株式会社 | 鞘氨醇-1-磷酸结合抑制物质 |
| BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
| WO2008055072A2 (fr) | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions et procédés pour traiter des maladies et des troubles oculaires |
| CA2666709A1 (fr) | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Procede pour traiter une degenerescence maculaire liee a l'age |
| EP2014653A1 (fr) | 2007-06-15 | 2009-01-14 | Bioprojet | Nouveaux dérivés d'acide dicarboxylique comme agonistes du recepteur S1P1 |
| DK2177512T3 (da) | 2007-08-01 | 2012-06-18 | Taisho Pharmaceutical Co Ltd | S1P1-bindingshæmmer |
| KR101589332B1 (ko) | 2008-12-05 | 2016-01-27 | 아스텔라스세이야쿠 가부시키가이샤 | ２ｈ-크로멘 화합물 및 그의 유도체 |
| JP2013508385A (ja) | 2009-10-23 | 2013-03-07 | アラーガン インコーポレイテッド | 治療上有用な、受容体修飾薬としてのクマリン化合物 |
| CA2780987C (fr) | 2009-11-24 | 2018-03-06 | Allergan, Inc. | Nouveaux composes servant de modulateurs de recepteurs presentant une utilite therapeutique |
| WO2011087066A1 (fr) | 2010-01-14 | 2011-07-21 | 株式会社三和化学研究所 | Produit pharmaceutique destiné au traitement prophylactique ou thérapeutique de troubles accompagnés d'une angiogenèse oculaire et/ou d'une perméabilité vasculaire oculaire supérieure à la normale |
| US8273776B2 (en) | 2010-04-16 | 2012-09-25 | Allergan, Inc | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators |
| US8530462B2 (en) | 2010-11-24 | 2013-09-10 | Allergan, Inc. | Indole modulators of S1P receptors |
| EP2643303A1 (fr) | 2010-11-24 | 2013-10-02 | Allergan, Inc. | Modulateurs de récepteurs de la s1p |
| BR112013013633A2 (pt) | 2010-12-03 | 2016-11-08 | Allergan Inc | derivados de alquina e alceno como moduladores do receptor de esfingosina 1-fosfato-1 |
| WO2012105610A1 (fr) | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | Agent médicinal pour la prévention ou le traitement de maladies associées à une néovascularisation intraoculaire et/ou une hyperperméabilité vasculaire intraoculaire |
| CA2833305A1 (fr) | 2011-04-14 | 2012-10-18 | Allergan, Inc. | Derives de methylazetidines bicycliques phenyliques en tant que modulateurs des recepteurs de sphingosine-1 phosphate |
| WO2012145236A1 (fr) | 2011-04-18 | 2012-10-26 | Allergan, Inc. | Dérivés de méthylamines bicycliques substitués à titre de modulateurs des récepteurs de sphingosine-1 phosphate |
| US9000016B2 (en) | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
| US8735433B1 (en) | 2012-11-14 | 2014-05-27 | Allergan, Inc. | Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| WO2014130565A1 (fr) | 2013-02-20 | 2014-08-28 | Allergan, Inc. | Dérivés de diaryle azétidine substitués utilisés en tant que modulateurs des récepteurs de la sphingosine |
| WO2014175287A1 (fr) | 2013-04-26 | 2014-10-30 | 国立大学法人 京都大学 | Composition médicinale destinée à empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou réduire un tel anévrisme |
| JP2018016911A (ja) | 2016-07-28 | 2018-02-01 | 村田機械株式会社 | 解析装置 |
-
2019
- 2019-02-01 US US16/966,757 patent/US20210113529A1/en not_active Abandoned
- 2019-02-01 JO JOP/2020/0186A patent/JOP20200186A1/ar unknown
- 2019-02-01 WO PCT/JP2019/003573 patent/WO2019151470A1/fr unknown
- 2019-02-01 CA CA3089952A patent/CA3089952A1/fr active Pending
- 2019-02-01 MX MX2020007948A patent/MX2020007948A/es unknown
- 2019-02-01 RU RU2020128700A patent/RU2020128700A/ru unknown
- 2019-02-01 BR BR112020015567-5A patent/BR112020015567A2/pt not_active IP Right Cessation
- 2019-02-01 SG SG11202006255UA patent/SG11202006255UA/en unknown
- 2019-02-01 JP JP2019569604A patent/JPWO2019151470A1/ja active Pending
- 2019-02-01 EP EP19747229.3A patent/EP3747471A4/fr not_active Withdrawn
- 2019-02-01 AU AU2019214265A patent/AU2019214265A1/en not_active Abandoned
- 2019-02-01 KR KR1020207024569A patent/KR20200116953A/ko not_active Application Discontinuation
- 2019-02-01 MA MA053098A patent/MA53098A/fr unknown
- 2019-02-01 CN CN201980010708.6A patent/CN111683682A/zh active Pending
-
2020
- 2020-06-23 IL IL275603A patent/IL275603A/en unknown
- 2020-06-29 PH PH12020551015A patent/PH12020551015A1/en unknown
- 2020-07-14 ZA ZA2020/04327A patent/ZA202004327B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3089952A1 (fr) | 2019-08-08 |
| BR112020015567A2 (pt) | 2021-02-02 |
| EP3747471A1 (fr) | 2020-12-09 |
| SG11202006255UA (en) | 2020-07-29 |
| PH12020551015A1 (en) | 2021-09-06 |
| US20210113529A1 (en) | 2021-04-22 |
| ZA202004327B (en) | 2022-01-26 |
| RU2020128700A (ru) | 2022-03-02 |
| RU2020128700A3 (fr) | 2022-03-02 |
| JPWO2019151470A1 (ja) | 2021-02-25 |
| WO2019151470A1 (fr) | 2019-08-08 |
| MX2020007948A (es) | 2020-12-10 |
| AU2019214265A1 (en) | 2020-07-23 |
| JOP20200186A1 (ar) | 2020-07-29 |
| CN111683682A (zh) | 2020-09-18 |
| EP3747471A4 (fr) | 2021-10-27 |
| IL275603A (en) | 2020-08-31 |
| KR20200116953A (ko) | 2020-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53098A (fr) | Médicament pour prévenir ou traiter une maladie ophtalmique associée à une néovascularisation intraoculaire et/ou à une perméabilité vasculaire intraoculaire accrues | |
| PH12017500843A1 (en) | Methods for treating ocular diseases | |
| MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| IL278178A (en) | Use of pilocarpine hydrochloride to treat eye disorder | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA52616A (fr) | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| IL277557A (en) | Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases | |
| MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines | |
| MA54132A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 | |
| IL284344A (en) | Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye | |
| MA53268A (fr) | Mini-gde pour le traitement de la maladie de stockage du glycogène iii | |
| MA53252A (fr) | Thérapie génique non perturbatrice pour le traitement d'un mma | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA45997A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA52137A (fr) | Méthodes de traitement de l'amylose ttr à l'aide d'ag10 | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| MX2020009532A (es) | Oligonucleotidos modificados para uso en el tratamiento de tauopatias. | |
| MA56220A (fr) | Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil | |
| EP3737381A4 (fr) | Dispositif médical et composition pharmaceutique pour le traitement d'une maladie ou affection de l'oeil | |
| MA52457A (fr) | Combinaison pharmaceutique et son utilisation pour le traitement de synucléinopathies | |
| EP3639854A4 (fr) | Médicament contenant un inhibiteur de mtor destiné au traitement ou à la prévention de symptômes, de troubles ou de maladies ophtalmiques, et son application | |
| IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases |